Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045777794> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2045777794 abstract "Background: BMN 673 is the most potent and specific inhibitor of poly-ADP ribose polymerase (PARP) 1 and 2 in clinical development (IC50 Methods: In this 2-stage study, patients with solid tumors including BRCA-related cancers, were enrolled during dose-escalation followed by an expansion phase at the MTD in breast, ovarian, and pancreatic cancer patients with deleterious germline BRCA mutations and in small cell lung cancer and Ewing sarcoma patients to further characterize safety and efficacy. This abstract summarizes demographics and safety for all patients and efficacy for patients with BRCA-related cancers. Results: As of 17May2013, a total of 1 pancreatic, 18 breast (17F/1M), and 28 ovarian cancer pts with germline BRCA mutations were enrolled at doses from 100-1100 μg/day. All breast cancer patients were treated from 900-1100 μg/day. The median (range) age for all 70 patients is 51.5 (18-81), PS 0 (0-1) and # of prior therapies 4 (1-13), with 47 patients having deleterious BRCA mutations. An MTD of 1000 μg/day was established with thrombocytopenia being dose-limiting. Related adverse events occurring in > 10% of all 70 patients included fatigue, nausea, alopecia, anemia, thrombocytopenia and neutropenia. One patient has had related grade 4 thrombocytopenia. Grade 3 related AE9s included fatigue in 1 patient (1%), anemia and thrombocytopenia in 9 each (13%) and neutropenia in 4 (6%). Dose reductions occurred in 11 pts due to myelosuppression. No patients discontinued for adverse events. Conclusions: BMN 673 is well tolerated with impressive anti-tumor activity in pts with deleterious germ line BRCA mutations. Myelosuppression and fatigue are the primary side effects associated with need for dose reduction. A phase 3 trial in metastatic breast cancer patients with deleterious germ line BRCA mutations is planned with single-agent, once-daily oral dosing of 1000 μg (1 mg) per day. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-02." @default.
- W2045777794 created "2016-06-24" @default.
- W2045777794 creator A5000603863 @default.
- W2045777794 creator A5011633842 @default.
- W2045777794 creator A5019071326 @default.
- W2045777794 creator A5022349981 @default.
- W2045777794 creator A5023538369 @default.
- W2045777794 creator A5029760021 @default.
- W2045777794 creator A5033786876 @default.
- W2045777794 creator A5057159153 @default.
- W2045777794 creator A5057815390 @default.
- W2045777794 creator A5062639474 @default.
- W2045777794 creator A5072378199 @default.
- W2045777794 creator A5077653682 @default.
- W2045777794 date "2013-12-15" @default.
- W2045777794 modified "2023-09-26" @default.
- W2045777794 title "Abstract P2-09-02: BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations" @default.
- W2045777794 doi "https://doi.org/10.1158/0008-5472.sabcs13-p2-09-02" @default.
- W2045777794 hasPublicationYear "2013" @default.
- W2045777794 type Work @default.
- W2045777794 sameAs 2045777794 @default.
- W2045777794 citedByCount "2" @default.
- W2045777794 countsByYear W20457777942017 @default.
- W2045777794 countsByYear W20457777942020 @default.
- W2045777794 crossrefType "proceedings-article" @default.
- W2045777794 hasAuthorship W2045777794A5000603863 @default.
- W2045777794 hasAuthorship W2045777794A5011633842 @default.
- W2045777794 hasAuthorship W2045777794A5019071326 @default.
- W2045777794 hasAuthorship W2045777794A5022349981 @default.
- W2045777794 hasAuthorship W2045777794A5023538369 @default.
- W2045777794 hasAuthorship W2045777794A5029760021 @default.
- W2045777794 hasAuthorship W2045777794A5033786876 @default.
- W2045777794 hasAuthorship W2045777794A5057159153 @default.
- W2045777794 hasAuthorship W2045777794A5057815390 @default.
- W2045777794 hasAuthorship W2045777794A5062639474 @default.
- W2045777794 hasAuthorship W2045777794A5072378199 @default.
- W2045777794 hasAuthorship W2045777794A5077653682 @default.
- W2045777794 hasConcept C104317684 @default.
- W2045777794 hasConcept C121608353 @default.
- W2045777794 hasConcept C126322002 @default.
- W2045777794 hasConcept C143998085 @default.
- W2045777794 hasConcept C182979987 @default.
- W2045777794 hasConcept C185592680 @default.
- W2045777794 hasConcept C197934379 @default.
- W2045777794 hasConcept C2776694085 @default.
- W2045777794 hasConcept C2777063308 @default.
- W2045777794 hasConcept C2778248108 @default.
- W2045777794 hasConcept C2779138821 @default.
- W2045777794 hasConcept C2780194787 @default.
- W2045777794 hasConcept C2780210213 @default.
- W2045777794 hasConcept C2780427987 @default.
- W2045777794 hasConcept C530470458 @default.
- W2045777794 hasConcept C55493867 @default.
- W2045777794 hasConcept C71924100 @default.
- W2045777794 hasConcept C82381507 @default.
- W2045777794 hasConcept C90924648 @default.
- W2045777794 hasConceptScore W2045777794C104317684 @default.
- W2045777794 hasConceptScore W2045777794C121608353 @default.
- W2045777794 hasConceptScore W2045777794C126322002 @default.
- W2045777794 hasConceptScore W2045777794C143998085 @default.
- W2045777794 hasConceptScore W2045777794C182979987 @default.
- W2045777794 hasConceptScore W2045777794C185592680 @default.
- W2045777794 hasConceptScore W2045777794C197934379 @default.
- W2045777794 hasConceptScore W2045777794C2776694085 @default.
- W2045777794 hasConceptScore W2045777794C2777063308 @default.
- W2045777794 hasConceptScore W2045777794C2778248108 @default.
- W2045777794 hasConceptScore W2045777794C2779138821 @default.
- W2045777794 hasConceptScore W2045777794C2780194787 @default.
- W2045777794 hasConceptScore W2045777794C2780210213 @default.
- W2045777794 hasConceptScore W2045777794C2780427987 @default.
- W2045777794 hasConceptScore W2045777794C530470458 @default.
- W2045777794 hasConceptScore W2045777794C55493867 @default.
- W2045777794 hasConceptScore W2045777794C71924100 @default.
- W2045777794 hasConceptScore W2045777794C82381507 @default.
- W2045777794 hasConceptScore W2045777794C90924648 @default.
- W2045777794 hasLocation W20457777941 @default.
- W2045777794 hasOpenAccess W2045777794 @default.
- W2045777794 hasPrimaryLocation W20457777941 @default.
- W2045777794 isParatext "false" @default.
- W2045777794 isRetracted "false" @default.
- W2045777794 magId "2045777794" @default.
- W2045777794 workType "article" @default.